Oncolytics Biotech (ONCY) Research & Development (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Research & Development of $5.5 million for Q3 2025, up 9.64% year-over-year from $5.0 million in Q3 2024, and up 169.36% quarter-over-quarter from $2.0 million in Q2 2025.
Oncolytics Biotech (ONCY) Research & Development (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Research & Development for 17 consecutive years, with $5.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Research & Development rose 9.64% year-over-year to $5.5 million; the TTM figure through Sep 2025 stood at $13.6 million (down 15.03% YoY), while the FY2025 annual figure was $13.3 million, down 13.79% from the prior year.
- Research & Development rose to $5.5 million in Q3 2025 per ONCY's latest filing, from $2.0 million in the prior quarter.
- Across five years, Research & Development topped out at $5.5 million in Q3 2025 and bottomed at $2.0 million in Q2 2025.
- Historically, Research & Development has averaged $3.2 million across 5 years, with a median of $2.9 million in 2021.
- Annual changes were most pronounced in 2024 — Research & Development jumped 62.81% — and 2025, when it sank 39.17%.
- Oncolytics Biotech's Research & Development stood at $2.9 million in 2021, then grew by 22.21% to $3.6 million in 2022, then fell by 4.08% to $3.4 million in 2023, then retreated by 4.76% to $3.3 million in 2024, then soared by 67.58% to $5.5 million in 2025.
- Business Quant data shows ONCY's Research & Development at $5.5 million in Q3 2025, $2.0 million in Q2 2025, and $2.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 97.90 Mn |
| 10 | Oncolytics Biotech | 98.21 Mn | 98.21 Mn | - | 4.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | 4.98 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 4.26 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 4.33 Mn |
| Jun 30, 2023 | 2.76 Mn |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | 3.57 Mn |
| Sep 30, 2022 | 2.82 Mn |
| Jun 30, 2022 | 2.51 Mn |
| Mar 31, 2022 | 2.93 Mn |
| Dec 31, 2021 | 2.92 Mn |
| Sep 30, 2021 | 2.60 Mn |
| Jun 30, 2021 | 2.61 Mn |
| Mar 31, 2021 | 2.18 Mn |